DENTSPLY SIRONA Inc. $XRAY Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 4.7% in the 1st quarter, Holdings Channel reports. The firm owned 1,569,358 shares of the medical instruments supplier’s stock after selling 77,513 shares during the quarter. Renaissance Technologies LLC’s holdings in DENTSPLY SIRONA were worth $18,205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of DENTSPLY SIRONA in the 1st quarter valued at about $26,000. Eurizon Capital SGR S.p.A. acquired a new stake in DENTSPLY SIRONA during the fourth quarter worth about $26,000. Caitong International Asset Management Co. Ltd raised its stake in DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares during the period. Farther Finance Advisors LLC lifted its holdings in DENTSPLY SIRONA by 119.1% in the fourth quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock worth $43,000 after acquiring an additional 2,051 shares during the last quarter. Finally, Performa Ltd US LLC lifted its holdings in DENTSPLY SIRONA by 116.1% in the fourth quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 2,283 shares during the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on XRAY shares. BMO Capital Markets assumed coverage on DENTSPLY SIRONA in a report on Wednesday, July 8th. They set a “market perform” rating and a $12.00 target price for the company. Weiss Ratings lowered DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Mizuho lowered their price objective on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Citigroup initiated coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 target price on the stock. Finally, UBS Group reduced their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $13.46.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY opened at $13.74 on Friday. The firm’s 50 day moving average is $11.38 and its two-hundred day moving average is $11.84. The firm has a market capitalization of $2.75 billion, a P/E ratio of -4.36, a PEG ratio of 1.69 and a beta of 0.89. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA Inc. has a 52 week low of $9.40 and a 52 week high of $15.20.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The business had revenue of $880.00 million for the quarter, compared to analyst estimates of $841.80 million. During the same quarter in the prior year, the firm posted $0.43 earnings per share. The business’s quarterly revenue was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts anticipate that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current year.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director Brian P. Mckeon purchased 10,000 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was bought at an average price of $10.12 per share, with a total value of $101,200.00. Following the completion of the purchase, the director owned 10,000 shares in the company, valued at $101,200. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael J. Barber purchased 15,175 shares of the stock in a transaction dated Thursday, June 11th. The shares were acquired at an average cost of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the acquisition, the director directly owned 55,943 shares of the company’s stock, valued at approximately $552,716.84. This trade represents a 37.22% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 35,160 shares of company stock worth $351,179. 0.46% of the stock is owned by company insiders.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.